Cord Blood Banking Services Market is expected to reach $2,772 million by 2023
Cord blood
is a rich source of stem cells, which can be used to treat over 80 genetic
diseases. Chronic diseases such as cancer, diabetes, blood diseases, and immune
diseases can all be treated with cord blood stem cells. Even though only a small amount of cord blood can be collected from a single umbilical
cord, it contains a large number of stem cells and is the only type of stem
cell that can be stored for future use. These cells are collected from
hospitals and nursing homes and stored in cord blood banks for future use, with
a storage life of 20-25 years on average. Government officials have supported
cord blood stem cell research and clinical trials, increasing the interest of
healthcare companies in investing in research and commercialization of cord
blood stem cell therapies.
Since the
last 20 years, the market for cord blood banking services has grown. At the
moment, market competition is increasing, and companies are attempting to raise
awareness about the benefits of cord blood storage. For example, in 2014, Cord
Blood Registry and The Institute for Transfusion Medicine have joined forces to
launch a multi-year campaign to raise awareness about cord blood cells. With
the help of campaigns, expectant parents will be educated and guided about the
various financial schemes for storage and donation available for cord blood
banking, which is expected to boost the market growth.
The global cord
blood banking services market was valued at $1,126 million in 2016 and are
expected to reach $2,772 million by 2023, growing at a CAGR of 13.8 percent
between 2017 and 2023.
The global cord blood banking services industry is divided into two categories: storage
services and region. It is divided into two types based on storage services:
public cord blood banks and private cord blood banks. Geographically, it is
examined in North America, Europe, Asia-Pacific, and Latin America, and The Caribbean.
The
influence of driving factors is expected to outweigh the influence of
restraints. Furthermore, advancements in a therapeutic application, untapped
opportunities in developing regions, and awareness initiatives are expected to
open up new avenues for market growth soon.
North America
held the largest market share in 2016, and this trend is expected to
continue throughout the forecast period.
China Cord
Blood Corporation, Cord Blood America, Inc., CBR Systems, Inc., Cordlife Group
Limited, Cryo-Cell International, Inc., Cryo-Save AG, Lifeforce Cryobanks,
National Cord Blood Program, ViaCord, Inc., Virgin Health Bank, Cordova,
Americord, CryoHoldco, and Vita34 are among the key players in this market.
Maze Cord
Blood, The University of Colorado Cord Blood Bank, StemCyte, Cornell, Lifebank
USA, Cryoviva, Genecord, AlphaCord, FamilyCord, Cells4Life, Michigan Blood,
CariCord, and LifeCell are among the other prominent players in the value
chain.

Comments
Post a Comment